Jiangsu Hengrui Medicine
600276.SS
#390
Rank
S$78.18 B
Marketcap
S$11.78
Share price
0.11%
Change (1 day)
47.61%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

EPS for Jiangsu Hengrui Medicine (600276.SS)

EPS in 2025 (TTM): S$0.17

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current EPS (TTM) is S$0.16. In 2024 the company made an earnings per share (EPS) of S$0.18 an increase over its 2023 EPS that were of S$0.12.

EPS history for Jiangsu Hengrui Medicine from 2000 to 2025

Annual EPS

Year EPS Change
2025 (TTM)S$0.17-2.39%
2024S$0.1842.43%
2023S$0.128.77%
2022S$0.11-20.62%
2021S$0.14-26.59%
2020S$0.2027.24%
2019S$0.1528.41%
2018S$0.1220.04%
2017S$0.0995931.21%
2016S$0.0759011.46%
2015S$0.0680936.27%
2014S$0.0499719.77%
2013S$0.0417218.05%
2012S$0.0353423.9%
2011S$0.0285226.9%
2010S$0.0224812.37%
2009S$0.0200056.6%
2008S$0.012779.18%
2007S$0.01170114.48%
2006S$0.00545564.83%
2005S$0.00331035.55%
2004S$0.00244229.73%
2003S$0.00188219.86%
2002S$0.001570-2.71%
2001S$0.0016141.02%
2000S$0.001598